Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: A Children's Cancer Group study

Journal of Clinical Oncology

Volumn 23, Issue 27, 2005, Pages 6474-6480

  Schmidt, Mary Lou ^a   Lal, Ashutosh ^a   Seeger, Robert C ^a   Maris, John M ^a   Shimada, Hiroyuki ^a   O'Leary, Maura ^a   Gerbing, Robert B ^a   Matthay, Katherine K ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; ISOTRETINOIN; MELPHALAN; ONCOPROTEIN; PROTEIN MYCN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; HUMAN; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; AGE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; INFANT; MALE; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; ONCOGENE MYC; PATHOLOGY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURGERY; SURVIVAL; TREATMENT OUTCOME;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; INFANT; MALE; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SURGICAL PROCEDURES, OPERATIVE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 27244450637     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.183     Document Type: Article

References (22)

1. Castleberry RP, Pritchard J, Ambros P, et al: The International Neuroblastoma Risk Groups (INRG): A preliminary report. Eur J Cancer 33: 2113-2116, 1997
2. Maris J M, Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol 17:2264-2279, 1999
3. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
4. Schmidt ML, Lukens JN, Seeger RC, et al: Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol 18: 1260-1268, 2000
5. Goto S, Umehara S, Gerbing RB, et al: Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: A report from the Children's Cancer Group. Cancer 92:2699-2708, 2001
6. Matthay KK: Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma. Pediatr Transplant 3:72-77, 1999 (suppl 1)
7. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid: Children's Cancer Group. N Engl J Med 341:1165-1173, 1999
8. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124, 1984
9. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985
10. Seeger RC, Wada R, Brodeur GM, et al: Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 271:41-49, 1988
11. Crabbe DC, Peters J, Seeger RC: Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction. Diagn Mol Pathol 1:229-234, 1992
12. Shimada H, Chatten J, Newton WA Jr, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405-416, 1984
13. Chatten J, Shimada H, Sather HN, et al: Prognostic value of histopathology in advanced neuroblastoma: A report from the Childrens Cancer Study Group. Hum Pathol 19:1187-1198, 1988
14. Stram DO, Matthay KK, O'Leary M, et al: Myeloablative chemoradiotherapy versus continued chemotherapy for high risk neuroblastoma. Prog Clin Biol Res 385:287-291, 1994
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Look AT, Hayes FA, Shuster JJ, et al: Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:581-591, 1991
17. Quo C, White PS, Hogarty MD, et al: Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. Med Pediatr Oncol 35:544-546, 2000
18. Luttikhuis ME, Powell JE, Rees SA, et al: Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis. Br J Cancer 85:531-537, 2001
19. Breslow N, McCann B: Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 31:2098-2103, 1971
20. Hartmann O, Valteau-Couanet D, Vassal G, et al: Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 23:789-795, 1999
21. Stram DO, Matthay KK, O'Leary M, et al: Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies. J Clin Oncol 14:2417-2426, 1996
22. Shimada H, Umehara S, Monobe Y, et al: International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: A report from the Children's Cancer Group. Cancer 92:2451-2461, 2001